181 related articles for article (PubMed ID: 18604235)
1. Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.
Vos MA
Br J Pharmacol; 2008 Aug; 154(7):1523-7. PubMed ID: 18604235
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
Nalos L; Varkevisser R; Jonsson MK; Houtman MJ; Beekman JD; van der Nagel R; Thomsen MB; Duker G; Sartipy P; de Boer TP; Peschar M; Rook MB; van Veen TA; van der Heyden MA; Vos MA
Br J Pharmacol; 2012 Jan; 165(2):467-78. PubMed ID: 21718297
[TBL] [Abstract][Full Text] [Related]
3. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
Lee N; Authier S; Pugsley MK; Curtis MJ
Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
[TBL] [Abstract][Full Text] [Related]
4. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
Thomsen MB; Beekman JD; Attevelt NJ; Takahara A; Sugiyama A; Chiba K; Vos MA
Br J Pharmacol; 2006 Dec; 149(8):1039-48. PubMed ID: 17088870
[TBL] [Abstract][Full Text] [Related]
5. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
Pugsley MK; Hancox JC; Curtis MJ
Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin-induced torsades de pointes.
Sherazi S; DiSalle M; Daubert JP; Shah AH
Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
[TBL] [Abstract][Full Text] [Related]
7. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Chiba K; Sugiyama A; Hagiwara T; Takahashi S; Takasuna K; Hashimoto K
Eur J Pharmacol; 2004 Feb; 486(2):189-200. PubMed ID: 14975708
[TBL] [Abstract][Full Text] [Related]
8. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
10. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
Guns PJ; Johnson DM; Weltens E; Lissens J
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
[TBL] [Abstract][Full Text] [Related]
11. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
12. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.
Sugiyama A
Br J Pharmacol; 2008 Aug; 154(7):1528-37. PubMed ID: 18552873
[TBL] [Abstract][Full Text] [Related]
13. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
[TBL] [Abstract][Full Text] [Related]
14. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
16. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.
Joshi A; Dimino T; Vohra Y; Cui C; Yan GX
J Electrocardiol; 2004; 37 Suppl():7-14. PubMed ID: 15534787
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
[TBL] [Abstract][Full Text] [Related]
18. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
[TBL] [Abstract][Full Text] [Related]
19. Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.
Takahara A; Sugiyama A; Ishida Y; Satoh Y; Wang K; Nakamura Y; Hashimoto K
Br J Pharmacol; 2006 Mar; 147(6):634-41. PubMed ID: 16314854
[TBL] [Abstract][Full Text] [Related]
20. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.
Vargas HM
Br J Pharmacol; 2010 Dec; 161(7):1441-3. PubMed ID: 20698854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]